RS51381B - Tumor-povratne ćelije koje su konstruisane da proizvode ligand povezan sa tumor nekroznim faktorom koji indukuje apoptozu (trail) - Google Patents

Tumor-povratne ćelije koje su konstruisane da proizvode ligand povezan sa tumor nekroznim faktorom koji indukuje apoptozu (trail)

Info

Publication number
RS51381B
RS51381B RSP-2010/0179A RSP20100179A RS51381B RS 51381 B RS51381 B RS 51381B RS P20100179 A RSP20100179 A RS P20100179A RS 51381 B RS51381 B RS 51381B
Authority
RS
Serbia
Prior art keywords
cells
trail
tumor
apoptosis
cell
Prior art date
Application number
RSP-2010/0179A
Other languages
English (en)
Serbian (sr)
Inventor
Francesco Colotta
Alessandro M. Gianni
Carmelo Carlo-Stella
Original Assignee
Dompe`S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe`S.P.A. filed Critical Dompe`S.P.A.
Publication of RS51381B publication Critical patent/RS51381B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RSP-2010/0179A 2004-07-29 2005-07-21 Tumor-povratne ćelije koje su konstruisane da proizvode ligand povezan sa tumor nekroznim faktorom koji indukuje apoptozu (trail) RS51381B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Publications (1)

Publication Number Publication Date
RS51381B true RS51381B (sr) 2011-02-28

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0179A RS51381B (sr) 2004-07-29 2005-07-21 Tumor-povratne ćelije koje su konstruisane da proizvode ligand povezan sa tumor nekroznim faktorom koji indukuje apoptozu (trail)

Country Status (24)

Country Link
US (1) US20070264231A1 (OSRAM)
EP (2) EP1621550A1 (OSRAM)
JP (1) JP5042826B2 (OSRAM)
KR (1) KR20070047757A (OSRAM)
CN (1) CN101076540B (OSRAM)
AT (1) ATE455847T1 (OSRAM)
AU (1) AU2005266543B2 (OSRAM)
BR (1) BRPI0513855A (OSRAM)
CA (1) CA2571426A1 (OSRAM)
DE (1) DE602005019050D1 (OSRAM)
DK (1) DK1771468T3 (OSRAM)
ES (1) ES2340400T3 (OSRAM)
HR (1) HRP20100227T1 (OSRAM)
IL (1) IL180233A (OSRAM)
MX (1) MX2007001152A (OSRAM)
NO (1) NO20070956L (OSRAM)
NZ (1) NZ552223A (OSRAM)
PL (1) PL1771468T3 (OSRAM)
PT (1) PT1771468E (OSRAM)
RS (1) RS51381B (OSRAM)
RU (1) RU2390558C2 (OSRAM)
SI (1) SI1771468T1 (OSRAM)
WO (1) WO2006010558A1 (OSRAM)
ZA (1) ZA200701231B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503468A (ja) * 2004-06-18 2008-02-07 ジェネンテック・インコーポレーテッド Ａｐｏ２ｌレセプターアゴニストおよびｎｋ細胞活性化因子の使用方法
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
WO2008142862A1 (ja) * 2007-05-18 2008-11-27 National University Corporation Asahikawa Medical College 血管内皮前駆細胞の移植による抗がん療法
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
CN104160027B (zh) * 2012-02-01 2016-06-22 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
WO2016065330A1 (en) 2014-10-24 2016-04-28 Aladar Szalay Combination immunotherapy approach for treatment of cancer
CN116064401A (zh) * 2015-07-29 2023-05-05 昂克医疗有限公司 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US12220465B2 (en) 2018-11-28 2025-02-11 Washington University Compositions and methods for targeted treatment and imaging of cancer or tumors
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
CN113677791B (zh) * 2019-03-21 2024-12-03 昂克医疗有限公司 对细胞死亡具有增加的抗性的经修饰的免疫效应细胞
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
AU747602B2 (en) * 1997-06-04 2002-05-16 Oxford Biomedica (Uk) Limited Vector
WO2002022175A2 (en) * 2000-09-11 2002-03-21 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
EP1427813A2 (en) * 2000-10-24 2004-06-16 Immunex Corporation Method for dendritic cells-based immunotherapy of tumors using combination therapy
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
AU2005266543B2 (en) 2012-02-02
EP1771468B1 (en) 2010-01-20
EP1621550A1 (en) 2006-02-01
ZA200701231B (en) 2008-08-27
PL1771468T3 (pl) 2010-07-30
NZ552223A (en) 2009-01-31
EP1771468A1 (en) 2007-04-11
PT1771468E (pt) 2010-04-20
ATE455847T1 (de) 2010-02-15
CA2571426A1 (en) 2006-02-02
HK1110874A1 (en) 2008-07-25
WO2006010558A1 (en) 2006-02-02
RU2007107369A (ru) 2008-09-10
WO2006010558A8 (en) 2006-08-24
JP2008507961A (ja) 2008-03-21
DK1771468T3 (da) 2010-05-25
KR20070047757A (ko) 2007-05-07
CN101076540B (zh) 2012-10-24
IL180233A0 (en) 2007-07-04
US20070264231A1 (en) 2007-11-15
CN101076540A (zh) 2007-11-21
HRP20100227T1 (hr) 2010-07-31
RU2390558C2 (ru) 2010-05-27
MX2007001152A (es) 2007-04-18
NO20070956L (no) 2007-02-20
AU2005266543A1 (en) 2006-02-02
DE602005019050D1 (de) 2010-03-11
BRPI0513855A (pt) 2008-05-20
SI1771468T1 (sl) 2010-07-30
JP5042826B2 (ja) 2012-10-03
ES2340400T3 (es) 2010-06-02
IL180233A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
CN111201035A (zh) Il-2超激动剂、激动剂及其融合体的用途和方法
CN108018299A (zh) 靶向bcma的嵌合抗原受体及其用途
JP6552471B2 (ja) １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
EP1771468B1 (en) Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)
JP2021511060A (ja) 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現
US20210221903A1 (en) Bcma-targeting chimeric antigen receptor and uses thereof
CN113416260B (zh) 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用
US20240092852A1 (en) Multi-armed myxoma virus
JP2026510279A (ja) 膜結合サイトカインを発現する腫瘍浸潤リンパ球
KR20240050428A (ko) 키메라 항원 수용체(car) t 세포 요법 플랫폼
CN116059329A (zh) 溶瘤病毒与car t细胞联合治疗血液肿瘤的方法
CN111836888B (zh) 用于癌症治疗的工程化干细胞
CN115806626A (zh) 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用
CN120924501B (zh) 双基因工程化的间充质干细胞及其应用
US20250195634A1 (en) Novel usage of oncolytic gene-modified measles virus
HK1110874B (en) Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)
WO2022170919A1 (zh) 一种重组溶瘤腺病毒及其应用
WO2026007901A1 (zh) 共表达细胞因子的FLT3-CAR-γδT细胞及其应用
CN121130073A (zh) 一种增强nk细胞治疗非小细胞肺癌效果的组合物及其应用